PB2095: ELOTUZUMAB OR DARATUMUMAB IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE (EPD AND DPD) IN RELAPSED REFRACTORY MULTIPLE MYELOMA (RRMM): A NETWORK META-ANALYSIS
Tassia Cristina Decimoni,
Adriana Cury,
James Farrell,
Nicolas Bertin,
Claire Fischer,
Victor Genestier,
Jorge Vaz Pinto Neto,
Glaciano Ribeiro,
Angelo Maiolino
Affiliations
Tassia Cristina Decimoni
1 Bristol Myers Squibb, São Paulo, Brazil
Adriana Cury
1 Bristol Myers Squibb, São Paulo, Brazil
James Farrell
2 Bristol Myers Squibb, Dublin, Ireland
Nicolas Bertin
3 Amaris, Health Economics and Market Access, London, England, United Kingdom
Claire Fischer
4 Amaris, Health Economics and Market Access, Montreal, Canada
Victor Genestier
5 Amaris, Health Economics and Market Access, Toronto, Canada
Jorge Vaz Pinto Neto
6 Cettro, Centro de Câncer de Brasília, DF, Brazil
Glaciano Ribeiro
7 Hospital das Clínicas da Universidade Federal de Minas Gerais, MG, Brazil
Angelo Maiolino
8 Universidade Federal do Rio de Janeiro, RJ, Brazil
